Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies

Table 1 Summary of the 14 observational studies assessing the treatment outcomes for patients with MDR-TB under DOTS-Plus that were included in the meta-analysis (n = 14)

Study authors	Study location	Study period	Study design	Sample size	HIV (%)	Treatment duration	Treatment regimen
Kurbatova et al. [16]	Five countries^a	2000–2003	RC	1768	1.6		Individualized
Singla et al. [17]	India	2002–2006	RC	126	–	24–27 months	Standardized
Keshavjee et al. [18]	Russia	2000–2004	RC	579	0.9	≥24 months	Individualized
Riekstina et al. [19]	Latvia	2002	RC	75	–	24 months	Individualized
Cox et al. [20]	Karakalpakstan, Uzbekistan	2003–2005	PC	87	–	≥24 months	Individualized
Shin et al. [21]	Russia	2000–2002	RC	244	0	≥12 months	Individualized
Holtz et al. [22]	Latvia	2000	RC	167	–	12–18 months after conversion	Individualized
Leimane et al. [23]	Latvia	2000	RC	204	0.5	12–18 months after conversion	Individualized
Tupasi et al. [24]	Philippines	1999–2002	PC	149	–	≥24 Months	Individualized
Arora et al. [25]	India	2002–2005	RC	52	–	24 months	Standardized
Mitnick et al. [26]	Peru	1999–2002	RC	651	1.5	15 months after conversion	Standardized
Jain et al. [27]	India	2009	PC	130	–	24 months	Standardized
Farley et al. [28]	South Africa	2000–2004	PC	757	38	12–18 months after conversion	Standardized
Van Deun et al. [14]	Bangladesh	1997–1999	RC	58	–	24 months	Standardized